Hypogonadism related to crizotinib therapy

Implications for patient care

Authors

  • Suresh S. Ramalingam MD,

    Corresponding author
    1. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
    • Associate Professor, Winship Cancer Institute of Emory University, 1365 Clifton Road, C-3090, Atlanta, GA 30322

    Search for more papers by this author
    • Fax: (404) 778-5520

  • Alice T. Shaw MD, PhD

    1. Harvard Medical School and Massachusetts General Hospital Cancer Center, Boston, Massachusetts
    Search for more papers by this author

  • See original referenced article on pages 5302-9, this issue

Abstract

This Web-only perspective commentary titled, “Hypogonadism Related to Crizotinib Therapy: Implications for Patient Care,” discusses a previously unreported side effect of crizotinib use in males for treatment of nonsmall cell lung cancer.

Ancillary